COVID-19 Safety Precautions: Find the Latest Visitor and Mask Policies. Learn More
Clinical Trials Search
A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients with Advanced or Metastatic Urothelial Carcinoma
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
- To evaluate the clinical activity of sitravatinib in combination with PD-(L)1 checkpoint inhibitor regimens in patients with advanced or metastatic urothelial carcinoma
BMS-936558 (Nivolumab); Enfortumab Vedotin (Padcev); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Sitravatinib ()